Direkt zum Inhalt
Merck
  • Features of mometasone furoate nasal spray and its utility in the management of allergic rhinitis.

Features of mometasone furoate nasal spray and its utility in the management of allergic rhinitis.

Expert opinion on pharmacotherapy (2003-08-29)
Eric Schenkel
ZUSAMMENFASSUNG

Mometasone furoate aqueous nasal spray (NS; Nasonex, Schering Corporation), is a synthetic corticosteroid approved for the prophylaxis and treatment of seasonal allergic rhinitis (SAR) and the treatment of perennial allergic rhinitis (PAR) in patients >or= 12 years of age, and for the treatment of SAR and PAR in children as young as 2 years of age. Studies demonstrate that mometasone furoate NS is a potent, clinically effective and well-tolerated intranasal corticosteroid with negligible systemic activity and which offers the convenience of once-daily dosing.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Mometasonfuroat, ≥98% (HPLC)
USP
Mometasonfuroat, United States Pharmacopeia (USP) Reference Standard
Supelco
Mometasonfuroat, Pharmaceutical Secondary Standard; Certified Reference Material
Mometasonfuroat, European Pharmacopoeia (EP) Reference Standard